Ben Adams's profile photo

Ben Adams

Chichester

Senior Editor at Fierce Biotech

Senior Editor at FiercePharma

Senior editor of Fierce Pharma Marketing

Featured in: Favicon fiercebiotech.com Favicon fiercepharma.com Favicon bmj.com Favicon wealthofgeeks.com Favicon merryjane.com Favicon 3blmedia.com Favicon architectsjournal.co.uk Favicon metroactive.com Favicon indaily.com.au Favicon pmlive.com

Articles

  • FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall

    2 weeks ago | fiercebiotech.com | Ben Adams

    Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid safety concerns. In a statement released Tuesday, June 10, the Californian Big Pharma said trials of GS-1720, an investigational integrase strand transfer inhibitor, and/or GS-4182, an investigational capsid inhibitor, had been put on a full FDA hold. The drugs had been in two phase 2/3 tests known as WONDERS-1 and WONDERS-2, as well as three earlier phase 1 studies.

  • Stars align for CRISPR Tx, Sirius as pair pen siRNA collab with a focus on thrombotic disease

    1 month ago | fiercebiotech.com | Ben Adams

    CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the next-gen thrombotic disease asset SRSD107. That drug, Sirius’ lead program, works as a long-acting, next-generation anticoagulant for thromboembolic disorders that after passing early phase 1 tests is gearing up for midstage trials.

  • GSK pays $1.2B upfront for Boston Pharmaceuticals’ lead liver disease drug

    1 month ago | fiercebiotech.com | Ben Adams

    GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate for a hefty $1.2 billion upfront. That drug in question is efimosfermin, Boston Pharmaceuticals’ lead asset. The asset has already passed midstage tests and is in now a phase 3-ready therapy to help stop the progression of steatotic liver disease (SLD), a condition where fat builds up in the liver.

  • Arcturus stops work on early-stage vaccine programs in effort to ‘streamline resources’

    1 month ago | fiercebiotech.com | Ben Adams |Gabrielle Masson

    San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway.

  • Qilu Pharmaceutical pays $38M upfront for greater China rights to Minghui's ADC

    1 month ago | fiercebiotech.com | Ben Adams

    Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China biopharma Minghui Pharmaceutical. The pact centers on MHB088C, a B7-H3-targeted antibody-drug conjugate that is in trials for solid tumors, including in subgroups of patients with small cell lung cancer and metastatic castration-resistant prostate cancer.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map

X (formerly Twitter)

Followers
3K
Tweets
25K
DMs Open
No
BenAdamsFierce
BenAdamsFierce @PharmaceuticBen
31 Oct 24

RT @FierceBiotech: Step into Fierce Biotech’s graveyard, a yearly ritual in which we remember the biotechs shuttering operations. https://t…

BenAdamsFierce
BenAdamsFierce @PharmaceuticBen
30 Oct 24

RT @gliadkovskaya: 🏅Today's the 100th episode of #Podnosis!! To close out Menopause Awareness Month, I chatted with an OBGYN at @mavencli…

BenAdamsFierce
BenAdamsFierce @PharmaceuticBen
27 Oct 24

RT @bmj_latest: Pharma companies have paid an estimated £156 million to NHS trusts in England between 2015 and 2022 without the public bein…